

## Spike Protein RBD (B.1.617.2.1 Variant, K417N, L452R, T478K Mutation) Protein

Catalogue No.:abx620701

SARS-CoV-2 Spike Protein RBD (B.1.617.2.1 Variant, K417N, L452R, T478K Mutation) Protein is a recombinant Virus protein produced in a Mammalian cell expression system.

Target:	Spike Glycoprotein (S)
Target Modification:	Mutation
Modification:	K417N, L452R, T478K
Origin:	Virus
Expression:	Recombinant
Tested Applications	ELISA, WB, SDS-PAGE
Host:	Mammalian cells
Form:	Lyophilized
Purity:	> 90% (SDS-PAGE)
Reconstitution:	Reconstitute in sterile water to produce a stock solution.
Storage:	Store at 2-8 °C if the entire vial will be used within 1 week. Aliquot and store at -20 °C for long-term storage. Avoid repeated freeze-thaw cycles.
UniProt Primary AC:	P0DTC2 ( <u>UniProt</u> , <u>ExPASy</u> )
Molecular Weight:	Calculated MW: 28.1 kDa
Sequence Fragment: Arg319-Phe541	
Tag:	C-terminal His tag
Buffer:	Prior to lyophilization: PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol.
Activity:	Not tested
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
v1.0.0	Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951 1 of 1   Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413 Abbexa BV, Leiden, NL   Website: www.abbexa.com Email: info@abbexa.com Fmail: info@abbexa.com

Website: www.abbexa.com · Email: info@abbexa.com